Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Oral PCLX-001 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

NCT06613217 is registered in ClinicalTrials.gov with Pacylex Pharmaceuticals as lead sponsor.

NCT NCT06613217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06613217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Oral PCLX-001 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Lead sponsor
Pacylex Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
March 3, 2025
Completion date
September 1, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed adult aml